Psoriasis: patent license
GRANT OF THE PATENT
We have currently been granted the patent in 30 countries and are in the process of obtaining the patent in 22 additional countries.
This strain mixture is licensed in more than 20 countries around the world to several renowned international pharmaceutical companies.
If you want to check available territories, contact us.
Psoriasis is a systemic, inflammatory and multifactorial dermatological disease characterised by a chronic relapsing course, which has a significant impact on the social life of people with psoriasis (up to 11.4% of the world's population).
Treatment is based on the use of topical or systemic immunosuppressants, systemic corticosteroids, methotrexate or cyclosporine, or phototherapy. In recent years, there has been a push for antibody-based treatments, and although these drugs are more effective than topical or systemic immunosuppressants, they are expensive and can, in rare cases, cause serious side effects. In addition, in some cases, antibodies are produced against these drugs, reducing their efficacy.
Clinical Trial
TREATMENT WITH PROBIOTIC STRAIN MIXTURE
A double-blind, placebo-controlled clinical trial involving 90 patients with psoriasis was conducted to evaluate the efficacy of a probiotic strain mixture as a treatment for psoriasis.
INVESTIGATIONAL PRODUCT
Treatment consisted of taking one capsule per day of a probiotic mixture at a concentration of 1×10^9 cfu/capsule (or placebo comparator, where appropriate) for 12 weeks, while the patients continued their usual drug treatment.
These research results were published in Acta Dermato-Venereologica.
EVALUATION OF RESULTS.
After the end of the intervention period for all the patients involved, analysis of the results showed:
The variable that quantifies disease severity (PASI 75) showed a higher response rate in patients in the probiotic group than in the placebo group (66.7% vs. 45.2%) and a lower need for prescription of betamethasone steroids.
The probiotic mixture is an effective treatment for managing psoriasis which also reduces the time it takes for new outbreaks of the disease to appear, without the usual side effects of the drug treatments used to control this pathology.
The use of this probiotic mixture as a treatment for psoriasis was patented by Bioithas internationally through a PCT application (WO2017162683), and the patent is available to be licensed to other pharmaceutical laboratories abroad.
REQUEST MORE INFORMATION
All personal data that you submit us via this form will be processed by Data Controller BIOITHAS, S.L. and saved into CONTACTS processing activitie, with the purpose of answering your inquiry, via email or phone, and for a later follow up.
Processing shall be lawful because you give us your consent for these specific purposes. Your personal data will not be disclosed to third parties unless forced by law. You have right to access to, rectify, or delete your personal data, and other rights as explained in our Privacy Policy: https://www.adelopd.com/privacidad/bioithas-sl
Our accreditations
Innovative SME Seal
Innovative Technology-Based Enterprise (EIBT) Seal
BIOITHAS S.L. has been a beneficiary of the European Regional Development Fund.
A way to make Europe.